The Ireland-based firm said that the financing will support clinical trials of an HIV test and help the company to strengthen its product pipeline.

The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.

The firm executed contracts for 11 T2Dx instruments in the quarter and saw its sepsis test panel revenue increase 42 percent.

Last week, readers were most interested in a story about a new respiratory test launched by Roche leveraging a new PCR technology.

The company aims to streamline its own lab operations while also enabling distribution of its Alzheimer's tests to outside ...

The methods use heat to create bubbles that collect target particles. The bubbles leave behind concentrated deposits as they cool and shrink.

Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space ...

The firm will enter studies this month aimed at obtaining CLIA waiver for its FDA-cleared FebriDx assay to distinguish bacterial from non-bacterial infections.

The firm raised $7.5 million in its financing round and plans to use the money for further development of its platform and regulatory milestones.

The company was accused of billing the federal government for medically unnecessary urine drug tests and providing kickbacks to physicians.

Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.

Jeffrey Madison had been accused of participation in a scheme to pay kickbacks to physicians for testing referrals and billing healthcare programs for the tests.